Viatris, Inc. (VTRS)
17.09
+0.46
(+2.77%)
USD |
NASDAQ |
Sep 02, 16:00
17.09
0.00 (0.00%)
After-Hours: 16:40
Viatris Research and Development Expense (Annual) : 952.50M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 952.50M |
| December 31, 2024 | 802.90M |
| December 31, 2023 | 793.00M |
| December 31, 2022 | 660.80M |
| December 31, 2021 | 737.80M |
| December 31, 2020 | 507.50M |
| December 31, 2019 | 639.90M |
| December 31, 2018 | 686.90M |
| December 31, 2017 | 774.90M |
| December 31, 2016 | 819.10M |
| December 31, 2015 | 671.90M |
| December 31, 2014 | 581.80M |
| December 31, 2013 | 456.22M |
| December 31, 2012 | 388.94M |
| December 31, 2011 | 294.73M |
| December 31, 2010 | 282.15M |
| December 31, 2009 | 275.26M |
| December 31, 2008 | 317.22M |
| December 31, 2007 | 194.75M |
| March 31, 2006 | 101.06M |
| March 31, 2005 | 87.88M |
| March 31, 2004 | 100.81M |
| March 31, 2003 | 86.75M |
| Date | Value |
|---|---|
| March 31, 2002 | 58.85M |
| March 31, 2001 | 64.38M |
| March 31, 2000 | 49.12M |
| March 31, 1999 | 61.84M |
| March 31, 1998 | 46.28M |
| March 31, 1997 | 42.63M |
| March 31, 1996 | 38.91M |
| March 31, 1995 | 30.53M |
| March 31, 1994 | 21.65M |
| March 31, 1993 | 13.52M |
| March 31, 1992 | 7.885M |
| March 31, 1991 | 6.293M |
| March 31, 1990 | 6.07M |
| March 31, 1989 | 5.361M |
| March 31, 1988 | 4.513M |
| March 31, 1987 | 4.489M |
| March 31, 1986 | 4.061M |
| March 31, 1985 | 3.032M |
| March 31, 1984 | 2.56M |
| March 31, 1983 | 1.724M |
| March 31, 1982 | 0.965M |
| March 31, 1981 | 0.56M |
| March 31, 1980 | 0.297M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc. | 10.25B |
| Eli Lilly & Co. | 13.34B |
| Merck & Co., Inc. | 12.51B |
| Bristol Myers Squibb Co. | 9.492B |
| Johnson & Johnson | 14.83B |